CSL stock: Buy, hold, or sell in 2025?

Let's see what analysts are saying about this blue chip giant at the start of the year.

| More on:
Woman using a pen on a digital stock market chart in an office.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

CSL Ltd (ASX: CSL) stock had an underwhelming year in 2024.

During the 12 months, the biotechnology giant's shares traded relatively flat and underperformed the market.

While this is disappointing, has it created a buying opportunity for investors in 2025? Let's find out.

CSL stock: Buy, hold, or sell in 2025?

The good news is that almost all the major brokers currently have the equivalent of buy ratings on CSL's shares at the start of 2025.

The even better news is that the general consensus is that CSL stock could generate big returns over the next 12 months.

Let's look at what a few brokers are saying about the plasma therapies leader.

Over at Morgans, its analysts have an add rating and $330.75 price target on the company's shares. This implies potential upside of almost 15% for investors from current levels.

The broker recently named CSL as one of its Best Calls to Action. It notes that these are "stocks that present compelling buying prospects right now."

Elsewhere, analysts at Macquarie have an outperform rating and $334.00 price target on CSL stock. This suggests that upside of approximately 16% is possible over the next 12 months.

In addition, the broker has previously stated its belief that CSL's shares could hit $500 within three years. This is based on its forecast for strong double-digit earnings growth for the foreseeable future thanks to the CSL Behring plasma business.

What else?

UBS is also bullish on CSL and has a buy rating and $330.00 price target on its shares, and Jarden has an overweight rating and $329.62 price target on them.

But the most bullish broker is arguably Bell Potter, which has a buy rating and $345.00 price target. This implies potential upside of almost 20% for investors in 2025.

Commenting on its buy rating, the broker said:

We expect CSL will achieve guidance of "annual double-digit earnings growth" over the mid-term driven largely by the legacy plasma business, Behring, particularly its immunoglobulin sales. While CSL's Seqirus and Vifor business units do face near-term headwinds (reduced flu market demand and generic iron competition), these two units combined only contribute less than a third of total earnings.

CSL continues to be a high quality, global operator with a multi-year gross margin recovery well underway to drive earnings expansion. The stock is currently trading at a 12m forward PE 27% and 19% below 5- and 10-year averages, respectively.

Overall, this could make the biotech giant one to consider this year.

Motley Fool contributor James Mickleboro has positions in CSL. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and Macquarie Group. The Motley Fool Australia has positions in and has recommended Macquarie Group. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

A young man sits at his desk working on his laptop with a big smile on his face.
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

man thinking about whether to invest in bitcoin
Broker Notes

Why Macquarie expects this ASX 200 dividend stock to keep outperforming

Macquarie has tipped this ASX 200 dividend stock to outperform. Let’s find out why.

Read more »

A man clenches his fists in excitement as gold coins fall from the sky.
Broker Notes

These ASX 200 shares could rise 20% to 35%

These shares are being tipped to deliver market-beating returns by analysts.

Read more »

Keyboard button with the word sell on it.
Broker Notes

8 ASX All Ords stocks downgraded to sell ratings

Find out which shares are out of favour with the experts.

Read more »

Woman smiling whilst shopping in a clothing store.
Dividend Investing

Why this quality ASX 300 dividend stock is tipped to surge 54%

A leading fund manager forecasts significant outperformance from this quality ASX 300 dividend stock.

Read more »

A group of businesspeople clapping.
Broker Notes

Bell Potter names more of the best ASX 200 stocks to buy in June

These stocks could be best buys this month according to the broker.

Read more »

A man sits thoughtfully on the couch with a laptop on his lap.
Broker Notes

Why Macquarie forecasts this ASX All Ords media company is set to surge 19%

Up 42% in 2025, here’s why this ASX All Ords media stock could keep racing higher into 2026.

Read more »

Excited couple celebrating success while looking at smartphone.
Broker Notes

Buy this ASX 200 stock for a 50% return: Bell Potter

Let's see why the broker is bullish on this name.

Read more »